A Single-center, single-blind, randomized, parallel-group trial comparing Olanexidine Gluconate with Povidone Iodine during Inguinal Hernioplasty.

A Single-center, single-blind, randomized, parallel-group trial comparing Olanexidine Gluconate with Povidone Iodine during Inguinal Hernioplasty. - A Single-center, single-blind, randomized, parallel-group trial comparing Olanexidine Gluconate with Povidone Iodine during Inguinal Hernioplasty.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040892

Enrollment

660

Registered

2020-06-25

Start date

2020-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal hernia

Interventions

Olanexidine gluconate is used for inguinal hernia surgery. Povidone iodine is used for inguinal hernia surgery.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are 20 years or older at the time of obtaining consent. 2. Performance Status (PS) is 0-1 of Eastern Cooperative Oncology Group (ECOG). 3. Patients whose function of main organ is maintained. A)WBC is 2,500 /mm3 or over. B)Hb is 8.0 g/dL or over. C)Plt is 75,000 /mm3 or over. D)T-Bil is 2.0 mg/dL or less. E)Cre is 3.0 mg/dL or less. 4. Patients who have sufficient judgment to understand the content of the study and who have obtained informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with severe ischemic heart disease (NYHA class III or higher). 2. Patients with liver cirrhosis or active hepatitis (liver damage C). 3. Patients with respiratory distress who need oxygen administration due to interstitial pneumonia or pulmonary fibrosis. 4. Patients undergoing dialysis due to chronic renal failure. 5. Patients with active cancer who are thought to affect adverse events. 6. Patients with allergies to beta-lactam antibiotics. 7. Patients who are allergic to olanexidine gluconate or povidone iodine. 8. Patients infected with planned skin incision. 9. Patients with psychosis or psychiatric symptoms who are considered difficult to participate in this study. 10. Patients who did not obtain consent to participate in this study. 11. Patients who are deemed inappropriate for conducting this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Incidence of surgical site infection within 90 days after surgery	—

Secondary

Measure	Time frame
1. Postoperative hospital stay 2. Outpatient revisit rate 3. Readmission rate 4. The incidence of postoperative hematoma 5. The incidence of surgical treatment for wounds 6. The incidence of all complications 7. Operative mortality	—

Countries

Japan

Contacts

Public ContactSatoru Nagatani

Hiroshima City Funairi Citizens Hospital Surgery

satorunagatani@gmail.com082-232-6195

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026